SecProbe.io - Filing

CORRESP Filing

Aspire Biopharma Holdings, Inc.
Date: April 18, 2025 · CIK: 0001847345 · Accession: 0001641172-25-005445

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-286444

Date

April 18, 2025

Author

Chief

Form

CORRESP

Company

Aspire Biopharma Holdings, Inc.

Letter

Aspire Biopharma Holdings, Inc.

Candelaro Drive, #233

Humacao, PR 00791

Tel: (908) 987-3002

April 18, 2025

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

F. Street, N.E.

Washington, D.C. 20549

Attention: Mr. Tyler Howes

Re: Aspire Biopharma Holdings, Inc. Registration Statement on Form S-1 File No. 333-286444

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time on April 21, 2025, or as soon thereafter as practicable.

Please contact Chance P. Moore, Esq. of Sichenzia Ross Ference Carmel LLP at (914) 355-8364, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.

Very
truly yours,
Aspire
Biopharma Holdings, Inc.

Show Raw Text

CORRESP
 1
 filename1.htm

 Aspire
Biopharma Holdings, Inc.

 194
Candelaro Drive, #233

 Humacao,
PR 00791

 Tel:
(908) 987-3002

 April
 18, 2025

 VIA
EDGAR

 United
States Securities and Exchange Commission

 Division
of Corporation Finance

 Office
of Life Sciences

 100
F. Street, N.E.

 Washington,
D.C. 20549

 Attention:
Mr. Tyler Howes

 Re:
 Aspire Biopharma Holdings, Inc.
 Registration
 Statement on Form S-1
 File
 No. 333-286444

 Ladies
and Gentlemen:

 Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for
the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time on
April 21, 2025, or as soon thereafter as practicable.

 Please
contact Chance P. Moore, Esq. of Sichenzia Ross Ference Carmel LLP at (914) 355-8364, as soon as the Registration Statement
has been declared effective, or if you have any other questions or concerns regarding this matter.

 Very
 truly yours,

 Aspire
 Biopharma Holdings, Inc.

 By:

 /s/
 Ernest Scheidemann

 Ernest
 Scheidemann

 Chief
 Financial Officer